BRAF KINASE INHIBITORS MARKET ANALYSIS

BRAF Kinase Inhibitors Market, by Drug (Vemurafenib, Dabrafenib, Lifirafenib, and Encorafenib), by Indication (Metastatic Melanoma, Metastatic Lung Cancer, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Published In : Oct 2020
Code : CMI4240
Pages :158
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

BRAF Kinase Inhibitors Market – Restraints

Medications and surgical operations are used to prevent or slow down further damage from occurring. Extensive R&D activities and manufacturing makes the drugs very expensive, which is expected to hamper the BRAF kinase inhibitors market growth over the forecast period. For instance, according to data published in National Center for Biotechnology Information (NCBI), by Experimental Hematology & Oncology, by year 7 of metastatic cancer, the cumulative costs per month were US$ 4,281 for ipilimumab, compared to US$ 8,920 for dabrafenib, US$ 10,211 for trametinib, US$ 11,002 for vemurafenib, and US$ 19,132 for dabrafenib + trametinib combination therapy.

Restraints & Challenges: